Index -
P/E -
EPS (ttm) -7.29
Insider Own 6.46%
Shs Outstand 92.17M
Perf Week -4.08%
Market Cap 5.05B
Forward P/E -
EPS next Y -5.28
Insider Trans -1.00%
Shs Float 86.21M
Perf Month -4.81%
Income -585.12M
PEG -
EPS next Q -1.48
Inst Own 96.70%
Short Float 3.35%
Perf Quarter 21.46%
Sales 481.30M
P/S 10.49
EPS this Y 22.42%
Inst Trans 10.70%
Short Ratio 4.26
Perf Half Y 21.46%
Book/sh 4.70
P/B 11.67
EPS next Y 17.55%
ROA -39.94%
Short Interest 2.89M
Perf Year 65.43%
Cash/sh 8.35
P/C 6.56
EPS next 5Y 37.90%
ROE -208.43%
52W Range 31.52 - 60.37
Perf YTD 14.58%
Dividend Est. -
P/FCF -
EPS past 5Y -15.75%
ROI -45.00%
52W High -9.24%
Beta 0.57
Dividend TTM -
Quick Ratio 3.39
Sales past 5Y 63.06%
Gross Margin 83.47%
52W Low 73.83%
ATR (14) 1.68
Dividend Ex-Date -
Current Ratio 3.54
EPS Y/Y TTM 28.85%
Oper. Margin -114.03%
RSI (14) 47.17
Volatility 2.71% 3.05%
Employees 1276
Debt/Eq 2.14
Sales Y/Y TTM 19.47%
Profit Margin -121.57%
Recom 1.20
Target Price 92.10
Option/Short Yes / Yes
LT Debt/Eq 2.01
EPS Q/Q 32.57%
Payout -
Rel Volume 0.51
Prev Close 54.46
Sales Surprise 19.34%
EPS Surprise 8.47%
Sales Q/Q 35.75%
Earnings Aug 01 AMC
Avg Volume 677.50K
Price 54.79
SMA20 -0.64%
SMA50 -1.82%
SMA200 15.13%
Trades
Volume 374,760
Change 0.61%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-06-24 Upgrade
Goldman
Neutral → Buy
$56 → $67
Apr-22-24 Initiated
RBC Capital Mkts
Outperform
$77
Dec-08-23 Initiated
Wells Fargo
Overweight
$72
Jun-14-23 Resumed
Credit Suisse
Outperform
$96
Jun-06-23 Upgrade
Evercore ISI
In-line → Outperform
$60 → $80
Apr-26-23 Initiated
Cantor Fitzgerald
Overweight
$114
Jan-18-23 Resumed
Canaccord Genuity
Buy
$90
Dec-30-22 Resumed
H.C. Wainwright
Buy
$82
Nov-03-22 Upgrade
Robert W. Baird
Neutral → Outperform
$50
Oct-13-22 Upgrade
Guggenheim
Neutral → Buy
$50
Aug-01-22 Downgrade
Evercore ISI
Outperform → In-line
$95 → $60
Mar-16-22 Upgrade
Credit Suisse
Neutral → Outperform
$99 → $105
Feb-11-22 Upgrade
JP Morgan
Neutral → Overweight
$132
Sep-30-21 Initiated
H.C. Wainwright
Buy
$106
Aug-19-21 Initiated
UBS
Sell
$73
Jul-15-21 Initiated
Guggenheim
Neutral
Jun-29-21 Upgrade
BofA Securities
Neutral → Buy
$162
Jun-04-21 Resumed
Robert W. Baird
Neutral
$109
May-06-21 Upgrade
Evercore ISI
In-line → Outperform
$144
May-06-21 Upgrade
Citigroup
Neutral → Buy
$160 → $151
Show Previous Ratings
Oct-18-24 04:30PM
Oct-07-24 08:00AM
Oct-03-24 04:30PM
Sep-26-24 08:00AM
Sep-18-24 05:00PM
01:07AM
Loading…
Sep-05-24 01:07AM
Sep-02-24 06:05PM
Aug-29-24 04:30PM
Aug-21-24 04:30PM
Aug-06-24 10:45AM
Aug-02-24 08:15AM
07:44AM
Aug-01-24 04:17PM
(Associated Press Finance)
04:05PM
Jul-25-24 04:05PM
08:00AM
Loading…
Jul-24-24 08:00AM
Jul-22-24 04:27PM
(Investor's Business Daily)
Jul-19-24 04:05PM
Jul-18-24 09:03AM
Jul-17-24 04:05PM
Jun-20-24 04:30PM
Jun-17-24 03:27PM
Jun-13-24 08:49PM
10:15AM
05:12AM
03:14AM
Jun-12-24 04:05PM
04:00PM
10:46AM
07:45AM
05:47PM
Loading…
Jun-11-24 05:47PM
Jun-04-24 04:05PM
May-31-24 10:36AM
May-30-24 04:00PM
May-22-24 02:27PM
May-17-24 04:30PM
May-07-24 04:30PM
May-04-24 10:24AM
May-03-24 03:01PM
12:22PM
May-02-24 08:58PM
08:00PM
05:49PM
05:10PM
04:08PM
(Associated Press Finance)
04:00PM
Apr-30-24 04:00PM
08:00AM
Apr-25-24 04:30PM
Apr-19-24 04:30PM
Apr-16-24 11:33AM
Apr-15-24 07:30AM
07:00AM
Apr-12-24 04:22PM
08:00AM
Mar-22-24 04:00PM
Mar-20-24 08:11AM
Mar-12-24 05:00PM
Mar-11-24 03:00PM
Mar-08-24 09:38AM
Feb-27-24 04:30PM
Feb-23-24 04:05PM
Feb-16-24 10:43AM
10:35AM
(Thomson Reuters StreetEvents)
07:53AM
Feb-15-24 04:15PM
(Associated Press Finance)
04:01PM
Feb-13-24 01:36PM
Feb-08-24 04:00PM
Feb-06-24 08:00AM
Feb-05-24 04:05PM
Jan-25-24 04:05PM
Jan-19-24 04:00PM
Jan-18-24 02:41PM
(Investor's Business Daily)
Jan-09-24 06:20PM
Jan-08-24 12:18PM
07:00AM
Jan-07-24 11:00AM
Jan-04-24 08:12AM
08:00AM
Jan-03-24 08:00AM
Jan-02-24 04:05PM
Dec-27-23 06:41PM
Dec-21-23 05:21PM
(The Wall Street Journal)
04:30PM
Dec-18-23 09:29AM
08:00AM
Dec-15-23 10:18AM
Nov-20-23 04:30PM
Nov-17-23 04:30PM
Nov-07-23 05:00PM
Nov-04-23 01:12PM
12:16PM
Nov-03-23 11:43AM
Nov-02-23 06:26PM
04:36PM
(Associated Press Finance)
04:05PM
Oct-26-23 04:05PM
Oct-25-23 06:17AM
Oct-23-23 04:01PM
Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Horn Howard Chief Financial Officer Oct 10 '24 Sale 52.76 7,465 393,853 92,301 Oct 11 04:48 PM KAKKIS EMIL D President & CEO Sep 03 '24 Sale 55.85 20,000 1,117,000 2,223,985 Sep 05 11:53 AM Huizenga Theodore Alan SVP, Chief Accounting Officer Sep 03 '24 Sale 56.19 91 5,113 41,551 Sep 05 11:50 AM KAKKIS EMIL D Officer Sep 03 '24 Proposed Sale 55.85 20,000 1,117,096 Sep 03 04:40 PM KAKKIS EMIL D President & CEO Aug 06 '24 Sale 50.17 20,000 1,003,400 2,243,985 Aug 07 02:48 PM KAKKIS EMIL D Officer Aug 06 '24 Proposed Sale 50.17 20,000 1,003,418 Aug 06 04:28 PM Sanders Corazon (Corsee) D. Director Jul 02 '24 Sale 40.98 584 23,932 12,009 Jul 03 02:07 PM Parschauer Karah Herdman EVP and Chief Legal Officer Jun 12 '24 Sale 45.00 9,806 441,270 57,981 Jun 12 07:47 PM Sanders Corazon (Corsee) D. Director Jun 10 '24 Sale 41.10 1,737 71,391 7,248 Jun 10 07:58 PM Crombez Eric EVP and Chief Medical Officer May 02 '24 Sale 43.66 354 15,456 48,431 May 03 03:23 PM Crombez Eric EVP and Chief Medical Officer Apr 18 '24 Sale 44.10 142 6,262 48,785 Apr 19 04:35 PM Kassberg Thomas Richard CBO & EVP Mar 11 '24 Sale 49.93 11,509 574,644 252,823 Mar 12 01:41 PM Fust Matthew K Director Mar 07 '24 Sale 50.88 12,195 620,443 14,860 Mar 11 12:54 PM Parschauer Karah Herdman EVP and Chief Legal Officer Mar 01 '24 Sale 53.76 3,756 201,923 67,340 Mar 05 08:22 PM Kassberg Thomas Richard CBO & EVP Mar 01 '24 Sale 53.76 1,011 54,351 264,332 Mar 05 08:19 PM Pinion John Richard See Remarks Mar 01 '24 Sale 53.76 4,173 224,340 89,268 Mar 05 08:15 PM Huizenga Theodore Alan SVP, Chief Accounting Officer Mar 01 '24 Sale 53.76 341 18,332 41,380 Mar 05 08:13 PM Crombez Eric EVP and Chief Medical Officer Mar 01 '24 Sale 53.76 1,238 66,555 48,927 Mar 05 08:10 PM Harris Erik EVP & Chief Commercial Officer Mar 01 '24 Sale 53.76 4,768 256,328 67,163 Mar 05 08:08 PM KAKKIS EMIL D President & CEO Feb 07 '24 Sale 45.00 30,000 1,350,000 539,770 Feb 08 03:49 PM KAKKIS EMIL D President & CEO Dec 29 '23 Sale 47.87 30,000 1,436,100 569,770 Jan 02 04:07 PM Huizenga Theodore Alan SVP, Chief Accounting Officer Jan 02 '24 Option Exercise 21.00 3,000 63,000 27,892 Jan 02 04:06 PM
Index RUT
P/E -
EPS (ttm) -3.58
Insider Own 35.50%
Shs Outstand 134.78M
Perf Week -1.81%
Market Cap 1.04B
Forward P/E -
EPS next Y -3.77
Insider Trans -0.03%
Shs Float 88.14M
Perf Month 0.13%
Income -483.04M
PEG -
EPS next Q -1.05
Inst Own 51.36%
Short Float 6.50%
Perf Quarter -24.65%
Sales 78.88M
P/S 13.18
EPS this Y 26.24%
Inst Trans -1.28%
Short Ratio 7.68
Perf Half Y -6.40%
Book/sh 10.50
P/B 0.73
EPS next Y -11.34%
ROA -24.69%
Short Interest 5.73M
Perf Year -9.94%
Cash/sh 8.53
P/C 0.89
EPS next 5Y 7.00%
ROE -29.78%
52W Range 7.12 - 13.09
Perf YTD -24.35%
Dividend Est. -
P/FCF -
EPS past 5Y -34.12%
ROI -31.60%
52W High -41.86%
Beta 0.45
Dividend TTM -
Quick Ratio 12.51
Sales past 5Y 421.39%
Gross Margin 73.88%
52W Low 6.88%
ATR (14) 0.29
Dividend Ex-Date Nov 03, 2010
Current Ratio 12.51
EPS Y/Y TTM -83.41%
Oper. Margin -648.66%
RSI (14) 47.41
Volatility 2.94% 3.89%
Employees 587
Debt/Eq 0.08
Sales Y/Y TTM -83.93%
Profit Margin -612.40%
Recom 1.78
Target Price 31.25
Option/Short Yes / Yes
LT Debt/Eq 0.07
EPS Q/Q 30.09%
Payout -
Rel Volume 0.83
Prev Close 7.65
Sales Surprise -59.14%
EPS Surprise -13.97%
Sales Q/Q -19.02%
Earnings Oct 31 AMC
Avg Volume 746.04K
Price 7.61
SMA20 0.95%
SMA50 -3.65%
SMA200 -18.24%
Trades
Volume 623,284
Change -0.52%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-29-24 Downgrade
JP Morgan
Overweight → Neutral
$23 → $9
Sep-08-23 Downgrade
BofA Securities
Buy → Neutral
$23 → $14
Mar-06-23 Upgrade
JP Morgan
Neutral → Overweight
$35 → $34
Feb-21-23 Upgrade
Goldman
Neutral → Buy
$41 → $53
Jan-27-23 Upgrade
Morgan Stanley
Underweight → Equal-Weight
$18 → $30
Sep-14-22 Initiated
SVB Leerink
Outperform
$40
Sep-09-22 Initiated
Morgan Stanley
Underweight
$15
Mar-03-22 Upgrade
Robert W. Baird
Underperform → Neutral
$36 → $28
Dec-21-21 Downgrade
Robert W. Baird
Neutral → Underperform
$36
Oct-25-21 Upgrade
JP Morgan
Underweight → Neutral
$29 → $37
Sep-22-21 Downgrade
Goldman
Buy → Neutral
$64 → $62
Jun-04-21 Resumed
Robert W. Baird
Neutral
$45
Jan-27-21 Downgrade
JP Morgan
Neutral → Underweight
$30
Jan-20-21 Reiterated
H.C. Wainwright
Buy
$100 → $125
Oct-05-20 Initiated
BofA Securities
Buy
$55
Sep-14-20 Upgrade
Goldman
Neutral → Buy
$48 → $54
Sep-11-20 Upgrade
JP Morgan
Underweight → Neutral
$29
Aug-20-20 Initiated
Needham
Buy
$62
Mar-19-20 Downgrade
JP Morgan
Neutral → Underweight
$26
Mar-13-20 Downgrade
Goldman
Buy → Neutral
Show Previous Ratings
Oct-18-24 03:04PM
Oct-17-24 04:30PM
Oct-15-24 08:16AM
Oct-03-24 04:00PM
Sep-10-24 08:05AM
04:05PM
Loading…
Sep-09-24 04:05PM
Sep-04-24 08:30AM
Aug-22-24 08:05AM
Aug-06-24 09:55AM
Aug-01-24 05:50PM
04:02PM
04:01PM
Jul-18-24 04:05PM
Jul-04-24 10:01AM
Jun-26-24 08:05AM
01:26PM
Loading…
Jun-06-24 01:26PM
Jun-05-24 02:51PM
05:30AM
May-29-24 04:05PM
08:05AM
May-23-24 04:05PM
May-22-24 08:05AM
May-21-24 08:17AM
May-13-24 07:21PM
May-09-24 10:46AM
May-07-24 09:55AM
May-03-24 01:05PM
06:05AM
(Thomson Reuters StreetEvents)
04:06AM
May-02-24 09:56PM
06:05PM
Loading…
06:05PM
04:05PM
Apr-30-24 04:05PM
Apr-24-24 12:00PM
Apr-18-24 08:00AM
Apr-11-24 04:30PM
Apr-04-24 07:01PM
Mar-22-24 07:00AM
Mar-19-24 02:58PM
Mar-13-24 11:07AM
Mar-05-24 08:05AM
Feb-23-24 01:54PM
(Thomson Reuters StreetEvents) +11.94%
10:34AM
09:55AM
08:05AM
Feb-22-24 05:50PM
04:05PM
Feb-20-24 04:30PM
Feb-14-24 03:45PM
Feb-01-24 04:05PM
Jan-15-24 11:32AM
Dec-17-23 07:00AM
07:00AM
Dec-13-23 04:05PM
Dec-06-23 04:05PM
Nov-30-23 06:10AM
Nov-13-23 08:00AM
Nov-10-23 08:00AM
Nov-08-23 08:05AM
Nov-04-23 11:42AM
Nov-03-23 09:02AM
(Thomson Reuters StreetEvents) +6.96%
Nov-02-23 07:00PM
04:05PM
Oct-30-23 08:00AM
Oct-23-23 02:50AM
Oct-12-23 04:05PM
Oct-11-23 08:00AM
Oct-05-23 04:30PM
Oct-03-23 07:59AM
Sep-20-23 08:00AM
Sep-19-23 05:07AM
Sep-08-23 09:34AM
Aug-29-23 04:30PM
Aug-12-23 11:05AM
Aug-11-23 10:15AM
Aug-07-23 06:03AM
Aug-04-23 01:40PM
Aug-03-23 06:05PM
04:05PM
Jul-26-23 04:05PM
Jul-21-23 10:11AM
Jul-20-23 04:50PM
(American City Business Journals) -44.90%
11:31AM
08:00AM
Jun-29-23 09:00AM
Jun-25-23 08:00AM
Jun-24-23 05:30AM
Jun-21-23 08:00PM
Jun-07-23 02:13AM
Jun-05-23 04:05PM
May-17-23 04:05PM
May-16-23 09:25AM
May-15-23 08:35AM
08:00AM
May-11-23 08:30AM
May-10-23 02:07PM
May-04-23 07:45PM
05:48PM
04:05PM
May-03-23 04:05PM
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Napolitano Janet Director Sep 09 '24 Sale 7.80 12,190 95,032 11,616 Sep 10 04:28 PM JANET ANN NAPOLITANO Director Sep 09 '24 Proposed Sale 7.76 12,190 94,594 Sep 09 04:29 PM Ramasastry Saira Director Jun 11 '24 Sale 10.95 4,000 43,789 14,619 Jun 12 12:21 PM De Backer Marianne Chief Executive Officer Apr 03 '24 Sale 9.46 72,995 690,365 678,457 Apr 04 04:14 PM HANLY ANN M. EVP & Chief Technology Officer Apr 01 '24 Sale 10.05 2,711 27,251 132,069 Apr 02 08:58 PM Lee Sung EVP & Chief Financial Officer Mar 27 '24 Sale 9.89 6,008 59,404 100,492 Mar 28 12:18 PM HANLY ANN M. EVP & Chief Technology Officer Feb 22 '24 Sale 10.05 12,296 123,521 134,780 Feb 26 07:34 PM Pang Phillip EVP & Chief Medical Officer Feb 22 '24 Sale 10.05 14,568 146,344 250,111 Feb 26 07:31 PM SCANGOS GEORGE A Director Feb 26 '24 Sale 11.65 17,722 206,522 112,989 Feb 26 07:30 PM SCANGOS GEORGE A Director Feb 22 '24 Sale 10.05 10,028 100,737 130,711 Feb 26 07:30 PM SCANGOS GEORGE A Director Feb 20 '24 Sale 10.22 16,872 172,385 140,739 Feb 20 09:02 PM SCANGOS GEORGE A Director Feb 16 '24 Sale 10.24 10,878 111,386 157,611 Feb 20 09:02 PM Pang Phillip EVP & Chief Medical Officer Feb 16 '24 Sale 10.24 3,321 34,006 264,679 Feb 16 06:56 PM Pang Phillip EVP & Chief Medical Officer Jan 02 '24 Option Exercise 1.38 80,000 110,299 268,000 Jan 03 02:47 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite